Results of Clinical Trial PA.6 Announced in Chicago

Clinical trial results performed in Canada and France using mFOLFIRINOX have shown that patients who undergo surgical removal of pancreatic cancer cells lived on average, 20 months longer than those who received gemicitabine. – Global News